Longwood Founders Fund

Investor type Venture Capital
Founders Christoph Westphal Michelle Dipp Richard Aldrich

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 3
Average round size
info
The average size of a deal this fund participated in
$96M
Portfolio companies 3
Rounds per year 0.27
Lead investments 1
Key employees Soon
Stages of investment
Early Stage Venture
Late Stage Venture
Private Equity

Areas of investment

  • Biotechnology
  • Pharmaceutical
  • Health Care
  • Medical
  • Biopharma
Summary

In 2010 was created Longwood Founders Fund, which is appeared as VC. The main office of represented VC is situated in the Boston. The fund was located in North America if to be more exact in United States.

For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Besides, a startup needs to be aged 4-5 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight TScan Therapeutics, Colorescience, Channel Medsystems. Among the most popular fund investment industries, there are E-Commerce, Life Science. The fund has no specific favorite in a number of founders of portfolio startups. When startup sums 5+ of the founder, the probability for it to get the investment is little.

The current fund was established by Christoph Westphal, Michelle Dipp, Richard Aldrich.

The fund is generally included in 2-6 deals every year. Deals in the range of 10 - 50 millions dollars are the general things for fund. The top amount of exits for fund were in 2017. Speaking about the real fund results, this VC is 11 percentage points more often commits exit comparing to other organizations. Comparing to the other companies, this Longwood Founders Fund performs on 17 percentage points more the average number of lead investments. The high activity for fund was in 2019.

The typical case for the fund is to invest in rounds with 5-6 participants. Despite the Longwood Founders Fund, startups are often financed by SV Health Investors, MPM Capital, Delphi Ventures. The meaningful sponsors for the fund in investment in the same round are MPM Capital, Bessemer Venture Partners, Novartis Venture Fund. In the next rounds fund is usually obtained by MPM Capital, Vertex Ventures, Cardinal Partners.

Read more

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Animal Capital California, Los Angeles, United States
Apollo Technology Partners -
Beneventure Capital Alabama, Birmingham, United States
Big Block Media -
Breakwater Investment Management California, Los Angeles, United States
Burwell Investments -
California Clean Energy Fund California, Oakland, United States
CRiF Bologna, Emilia-Romagna, Italy
Digital Pioneers Limburg, Maastricht, Netherlands
Heliocentris Berlin, Berlin, Germany
Juyuan Capital -
Lenovo Beijing, Beijing, China
Nire Capital -
Pacific Venture Group California, Encino, United States
Resolute Investment Managers Irving, Texas, United States
Snapdragon Capital Partners -
SunGate Capital Florida, United States, Winter Park
Tierra Del Oro Florida, Naples, United States

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Rectify Pharmaceuticals

Biotechnology
Life Science
Therapeutics
$100M14 Oct 2021 Cambridge, Massachusetts, United States

Axial Biotherapeutics

Biopharma
Biotechnology
Medical
Pharmaceutical
$37M13 Oct 2021 Massachusetts, United States

Pyxis Oncology

Biotechnology
Health Care
Pharmaceutical
$152M30 Mar 2021 Boston, Massachusetts, United States
News
ImmuneID Announces Close of $50 Million Series A Financing to Develop Precision Immunology Therapeutics

– ImmuneID, Inc. has raised $50m in Series A financing.
– The round was led by new investor Alta Partners and included new investors Alexandria Venture Investments, Redwood Capital Investments, Section 32 and Tekla Capital Management.
– All existing investors participated in the financing, including Arch Venture Partners, Longwood Fund, Pitango HealthTech, In-Q-Tel, Xfund and others.
– Proceeds from the financing will be used to advance the development of therapeutic candidates to treat autoimmune diseases, severe allergies, cancer and infectious diseases.

Interius BioTherapeutics Raises $76M in Series A Financing

– Interius BioTherapeutics, a Philadelphia, PA-based preclinical stage gene therapy company developing a paradigm-shifting platform for in vivo cell-specific gene delivery, raised $76m in Series A financing.
– The round was co-led by Cormorant Asset Management and Fairmount Funds, and joined by Bain Capital Life Sciences, Pfizer Ventures, RA Capital Management, Longwood Fund, Logos Capital, Osage University Partners and Quan Capital.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Longwood Founders Fund?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: